Clinicians flag trial-eligibility scoring as the weak spot in AI rare-disease trial matching
zakkohane · x · 2026-11-04
In a discussion around an AI project for matching rare-disease patients to clinical trials, Rea1Faisal argues that matching patients to trials they actually qualify for is where much of the value hides — and warns that trial-eligibility scoring is typically where such systems are confidently wrong, making the scoring approach a key open question.
More from AGI Musings
- Krishnan urges Democrats to craft sensible AI regulation, with Hassabis and Amodei as influencers — krishnan · 2026-11-05
- Same question to ChatGPT three years apart: from denying job fears to a blunt Yes — ChuckDBrooks · 2026-11-05
- "China only distills our models" is shaping up as official US policy narrative — teortaxesTex · 2026-11-05
- MIT's John Hart on AI in manufacturing and rebuilding US industrial capability — AnneliesGamble · 2026-11-05
- Redditor challenges the 'billionaires will control ASI' narrative — EndTiny3883 · 2026-11-05
- Nina Schick: Germany's nuclear exit leaves it uncompetitive in the AI industrial revolution — NinaDSchick · 2026-11-05